Astellas Pharma (OTCMKTS:ALPMY) Sets New 12-Month Low – Here’s What Happened

Astellas Pharma Inc. (OTCMKTS:ALPMY) hit a new 52-week low during trading on Friday . The stock traded as low as $9.05 and last traded at $9.60, with a volume of 228458 shares trading hands. The stock had previously closed at $9.44.

Astellas Pharma Price Performance

The firm has a market capitalization of $17.37 billion, a PE ratio of 45.72 and a beta of 0.34. The firm’s fifty day moving average price is $9.91 and its 200 day moving average price is $10.98. The company has a current ratio of 1.10, a quick ratio of 0.86 and a debt-to-equity ratio of 0.41.

Astellas Pharma (OTCMKTS:ALPMY) last released its quarterly earnings data on Wednesday, October 30th. The company reported $0.13 earnings per share for the quarter. Astellas Pharma had a return on equity of 10.40% and a net margin of 3.26%. The business had revenue of $3.11 billion during the quarter. As a group, equities analysts forecast that Astellas Pharma Inc. will post 0.61 earnings per share for the current year.

About Astellas Pharma

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.